Exosomes derived from platelet-rich plasma present a novel potential in repairing knee articular cartilage defect combined with cyclic peptide-modified β-TCP scaffold Authors: Xuchang Liu, Rudong Chen, Guanzheng Cui, Rongjie Feng, Kechun Liu Published: 2024 ABSTRACT AbstractBackgroundThe aim of this study was to investigate the therapeutic effects and mechanisms of PRP-exos combined with cyclic peptide-modified β-TCP scaffold in the treatment of rabbit knee cartilage defect.MethodsPRP-exos were extracted and characterized by TEM, NTA and WB. The therapeutic effects were evaluated by ICRS score, HE staining, Immunohistochemistry, qRT-PCR and ELISA. The repair mechanism of PRP-exos was estimated and predicted by miRNA sequencing analysis and protein–protein interaction network analysis.ResultsThe results showed that PRP-exos had a reasonable size distribution and exhibited typical exosome morphology. The combination of PRP-exos and cyclic peptide-modified β-TCP scaffold improved ICRS score and the expression level of COL-2, RUNX2, and SOX9. Moreover, this combination therapy reduced the level of MMP-3, TNF-α, IL-1β, and IL-6, while increasing the level of TIMP-1. In PRP-exos miRNA sequencing analysis, the total number of known miRNAs aligned across all samples was 252, and a total of 91 differentially expressed miRNAs were detected. The results of KEGG enrichment analysis and the protein–protein interaction network analysis indicated that the PI3K/AKT signaling pathway could impact the function of chondrocytes by regulating key transcription factors to repair cartilage defect.ConclusionPRP-exos combined with cyclic peptide-modified β-TCP scaffold effectively promoted cartilage repair and improved chondrocyte function in rabbit knee cartilage defect. Based on the analysis and prediction of PRP-exos miRNAs sequencing, PI3K/AKT signaling pathway may contribute to the therapeutic effect. These findings provide experimental evidence for the application of PRP-exos in the treatment of cartilage defect.Keywords: PRP-exos, Cyclic peptide, β-TCP scaffold, Cartilage defect, PI3K/AKT signaling pathway Introduction Articular cartilage plays a crucial role in providing a smooth and lubricated surface for joint movement, as well as absorbing and distributing mechanical loads [1]. However, due to its limited regenerative capacity, cartilage defect caused by trauma, degenerative diseases, or aging often lead to pain, functional impairment, and the progression of osteoarthritis (OA) [2]. Current treatment options for cartilage defect include conservative management, such as physical therapy and pain medication, as well as surgical interventions, such as microfracture [3]. However, these approaches have limitations, including limited long-term efficacy, donor site morbidity, and the formation of fibrocartilage rather than hyaline cartilage [4]. Regenerative medicine has emerged as a promising approach for cartilage repair and regeneration [5, 6]. Recently, there has been a notable growth in the use of platelet- rich plasma (PRP), for regenerative medicine applications [7], particularly in musculoskeletal medicine [8], and many serious disease areas are likely to benefit from PRP therapies [9]. PRP is an autologous blood-derived product containing a high concentration of platelets, growth factors, and cytokines, which encompasses research that falls in a variety of medical fields [10]: Eye surface in ophthalmology [11], regeneration of bone defects and periodontal tissues in dentistry [12–14], osteoarticular pathology, e.g., meniscal repair [15], knee osteoarthritis [16] or radiocarpal osteoarthritis [17]. Many studies have suggested that one of the key components in PRP responsible for its regenerative properties is exosomes [18]. Exosomes are small EVs with a diameter from 30 to 150 nm. They are formed from a sequential process of multivesicular body membrane remodeling. Exosomes are present in body fluids, including blood plasma, amniotic fluid, and umbilical cord-derived Wharton’s jelly [19]. Exosomes exhibit anti-inflammatory and pro-regenerative effects to stimulate healing in different tissue types [20]. Exosomes increase the secretion of cellular factors needed to hasten the healing of tendon injuries, acting via paracrine and autocrine processes [21]. Exosomes also stimulate repair of cartilage and proliferation of chondrocytes in osteoarthritis and help alleviate pain in knee OA [22]. Moreover, the immunomodulatory and tissue regeneration capabilities of exosomes may support their application as a prospective therapy for COVID-19 [23]. Exosomes as a cell-free therapeutic alternative to whole cell therapy with great regenerative potential was also reported [24]. Recent studies have shown that exosomes derived from platelet-rich plasma (PRP-exos) have regenerative potential in various tissues, including bone, muscle, and skin [25], but their specific mechanisms of action need to be further studied. β-tricalcium phosphate(β-TCP) is a commonly used scaffold material in tissue engineering due to its biocompatibility, osteoconductive, and ability to support cell adhesion and proliferation [26]. However, the lack of chondrogenic properties limits its application in cartilage repair. To overcome this limitation, cyclic peptides have been used to modify β-TCP scaffolds, enhancing their chondrogenic potential and promoting cartilage regeneration [27]. MiRNA have been shown to exist in exosomes [28], and miRNA have attracted the most attention, due to their high conservation across species and extensive regulatory roles in gene expression. The involvement of miRNAs in many biological activities has been well documented, including cell proliferation, cell differentiation, cell migration, disease initiation, and disease progression [29]. Accumulating evidence has shown that miRNAs can be directly delivered to target cells via exosomes, resulting in the functional modulation of mRNA targets and regulation of complex signaling pathways [30]. It has been also confirmed that miRNAs exist in PRP-exos [31], and whether they participate in the functional repair of PRP-exos and play an important role in it deserves further study. The aim of this study was to investigate the effects of PRP-exos combined with cyclic peptide-modified β-TCP scaffold in the treatment of knee articular cartilage defect. By combining PRP-exos with cyclic peptide-modified β-TCP scaffold, we anticipated that it could promote the proliferation and differentiation of chondrocytes, alleviate inflammatory responses, and provide a microenvironment conducive to the survival and function of chondrocytes, thereby facilitating the repair and regeneration of cartilage defect. Furthermore, a thorough investigation of PRP-exos including miRNAs sequencing analysis and prediction in this study was crucial for elucidating the mechanisms of action of the combined therapy and providing a more in-depth theoretical basis for clinical applications. Methods PRP extraction The present study was performed in compliance with Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All experimental procedures were approved by the Experimental Animal Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University (No. 2023-0026). Briefly, the whole blood was collected from New Zealand white rabbits purchased from Jinan Xinjian biological technology company by puncture of the central auricular artery and added to acid citrate dextrose solution A (ACD-A) anticoagulant (1 mL ACD-A/9 mL blood). To obtain platelet-containing plasma separate from erythrocytes and leukocytes, 10 mL of whole blood was centrifuged at 160 × g for 10 min in a 15 mL centrifuge tube. Then the separated plasma was added to another tube, and centrifuged again for 15 min at 250 × g. The supernatant plasma was discarded, before the platelet pellet was resuspended in the residual plasma to obtain 1 mL PRP. Extraction of PRP-exos The obtained PRP was centrifuged at 3000 g for 15 min at 4 °C in a conical tube. The PRP was mixed with 1 × volume of XBP buffer to obtain the PRP/XBP mixture. The mixture was centrifuged at 500 g for 1 min. This step was repeated until the total volume was less than 8 ml. The residual liquid was removed from the membrane by centrifugation at 5000 g for 1 min. 400 μl of Buffer XE was added to the membrane and incubated for 1 min. Centrifugation at 500 g, 5 min. Finally, the eluate was collected after centrifugation at 5000 g for 5 min. The eluate obtained from the exoEasy Maxi Kit [32] was used for the separation of exosomes. All steps were performed at 4 °C. The exosomes were carefully resuspended in sterile PBS and stored at − 80 °C for subsequent experiments. TEM observation of PRP-exos morphology The frozen storage tube containing PRP-exosomes was removed and allowed to thaw for 15 min. PBS was added for resuspension. 10 μl of exosome suspension was dropped onto a copper grid and allowed to settle for 1 min. Excess liquid was removed with filter paper along the edge of the copper grid. Then, 10 μl of uranyl acetate solution was dropped onto the exosome precipitate on the copper grid, allowed to stand for 1 min. Excess liquid was removed with filter paper, and the sample was air-dried at room temperature for 3–5 min. The PRP-exosome morphology was observed using TEM at an accelerating voltage of 100 kV. Nanoparticle tracking analysis for detection of PRP-exosome concentration and size distribution PRP-exosomes were resuspended in PBS and diluted at a ratio of 1:50, and 1 ml of the diluted exosome sample was added to the instrument's sample detection pool. Laser light was used to irradiate the exosome particle suspension. The concentration of exosomes was calculated by counting the number of scattered particles. The Brownian motion trajectory of exosome particles was also tracked. The mean square displacement of exosome particles was calculated over a unit time interval, and the size distribution of nanoparticles was calculated using the Stokes–Einstein equation. Western blotting analysis After PRP-exos extracted, western blotting analysis was subsequently performed as previously literature [33] to identify exosome surface markers, including CD9, TSG101, as well as the exosome-negative protein Calnexin. The steps were as follows: the total protein of PRP-exos were extracted and determined with a BCA protein assay kit (Pierce, Rockford, IL, USA). Then, 30 μg extracted cellular protein was mixed with loading buffer, denatured in boiling water for 5 min, and separated by 10% (w/v) sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane and blocked in 5% (w/v) bovine serum albumin (BSA, Sangon Biotech, Shanghai, China) for 1 h at room temperature. The membrane was probed with anti-CD9 (1:1000 dilution, Santa Cruz), anti-TSG101 (1:1000 dilution, Santa Cruz) and anti-Calnexin (1:1000 dilution Santa Cruz) overnight at 4 °C. After washing in Tris-buffered saline with Tween-20 (TBST), the membranes were treated with the corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies (1:3000 dilution, Cell Signaling Technology) at room temperature for 1 h. The excess secondary antibody was washed off by TBST, and the chemiluminescent signal was generated by the ECL imaging kit (Thermo Fisher Scientific, Waltham, MA, USA). Animal model All experimental and animal care procedures were approved by the Experimental Animal Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University (No. 2023-0026) and performed in accordance with the guidelines of the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Twenty-four New Zealand male rabbits (4-week-old, 2–3 kg) purchased from Jinan Xinjian biological technology company were utilized to establish the Cartilage defect model and undergo experiments. The rabbits were anesthetized, and the knee joint was prepared for surgery. The joint cavity was opened, and a chondral defect was created on the load-bearing area medial femoral condyle using a drill, resulting in a full-thickness osteochondral defect measuring 3 mm in length, 2 mm in width, and 1 mm in depth [34]. After rinsing with saline, the incision was sutured layer by layer. The rabbits were divided into four groups according to the experimental purpose: Group 1 (Control), Group 2 (PRP-exos), Group 3 (cyclic peptide-modified β-TCP scaffold), and Group 4 (PRP-exos + cyclic peptide-modified β-TCP scaffold), with 6 animals in each group. The control group underwent knee joint chondral defect modeling without any treatment. The group 2 underwent knee joint chondral defect modeling followed by PRP-exos injection. The group 3 underwent knee joint chondral defect modeling followed by scaffold implantation. The group 4 underwent knee joint chondral defect modeling followed by scaffold implantation and PRP-exos injection. After 8 weeks, all the New Zealand white rabbits were sacrificed by injecting an overdose of air, and the knee samples were harvested to assess cartilage repair based on the International Cartilage Repair Society (ICRS) gross morphology assessment scale [35]. Hematoxylin and eosin (HE) staining The cartilage tissue was sectioned and fixed, followed by washing with PBS solution for 3 times. The sample was incubated in hematoxylin solution at 60 °C for 10 min. After washing with PBS solution for 3 times, the sample was treated with 1% hydrochloric acid ethanol for 5 s. The sample was then incubated in 0.5% eosin solution at 60 °C for 10 min, followed by washing with PBS solution for 3 times. The sample was treated with a gradient of 75%, 80%, and 85% ethanol. After being treated with a gradient of xylene I and xylene II, the sample was fixed with neutral gum and observed under an inverted optical microscope to evaluate the cartilage repair situation in the HE stains. Immunohistochemistry The tibial articular cartilage tissue from each experimental animal group was prepared as paraffin tissue blocks. After sectioning and routine dewaxing, the samples were washed with PBS solution for 3 times. The samples were then incubated with goat serum, then coated with primary antibody against type II collagen and RUNX2 after being treated with the diluted primary antibody. Then incubated with rabbit anti-goat IgG secondary antibody in the dark for 30 min. The samples were fixed with neutral gum and observed under an inverted optical microscope. qRT-PCR After chloroform extraction achieved phase separation, the total RNA was then purified using isopropanol and ethanol, then diluted to an appropriate concentration with DEPC water. cDNA was synthesized according to the instructions of the reverse transcription kit. The amplification process was performed using a fluorescence quantitative PCR kit according to the instructions. The fluorescence data were collected for subsequent analysis. The results were interpreted using the 2-ΔΔCt method. The primer sequences are shown in Table 1. Table 1The sequences of primersForward primerReverse primerCOL25′-CTGTGAAGCCGACTCTGCCTAC-3′5′-ATCATCCTCATCGTTATCAGCATCAGT-3′RUNX25-CAGCAGCAGCAACAGCAACAG-35-CAGCACCGAGCACAGGAAGTT-3′SOX95′-AGAAGGAGAGCGAAGAGGACAAGTT-3′5′-TTGTTCTTGCTGGAGCCGTTGAC-3′GAPDH5-GAAGGTGGTGAAGCAGGCATCC-3′5-GCACTGTTGAAGTCGCAGGAGA-3′ The sequences of primers Enzyme-linked immunosorbent assay (ELISA) The serum samples of the respective group were collected and were centrifuged at 3000 rpm for 15 min immediately. And the supernatants were collected for further ELISA analysis. The serum levels of the MMP-3, TIMP-1, TNF-α, IL-1β and IL-6 were measured according to the manufacturer’s protocol. PRP-exos were subjected to miRNA sequencing analysis Exosomes were collected from PRP using established isolation protocols. The miRNA content of PRP-exos was then analyzed through high-throughput sequencing. According to the identified mature miRNA sequences and newly predicted miRNA sequences, expression levels were calculated using TPM (transcript per million) as the measurement index. TPM is calculated as the number of reads mapped to each miRNA divided by the total number of mapped reads in the sample, multiplied by 106. TPM represents the expression level of miRNA per million mapped sequence pairs, with the total number of mapped reads used for normalization. For samples with biological replicates, the DEG differential algorithm in the R package was used to calculate p values, and miRNAs with a P value < 0.05 were selected. The data after filtering against the Rfam database, species reference transcripts, and repetitive sequence databases were used for analysis of known miRNA alignment annotations, miRNA prediction, miRNA quantification, differential expression, target gene prediction, and enrichment analysis. KEGG and GO analysis of target genes were conducted using the hypergeometric distribution test in R software, and the P values were corrected for multiple testing using the Benjamini & Hochberg method to obtain the FDR. Statistical analysis Statistical analysis was performed using SPSS 20.0. Data are presented as mean ± standard deviation. Normally distributed data were compared using t-test. One-way analysis of variance was used for comparisons among multiple groups. A p-value ≤ 0.05 was considered statistically significant. Results Extraction and identification of PRP-exos Nanoparticle Tracking Analysis (NTA) technology is a commonly used technique for measuring the size distribution of particles. In this experiment, NTA was used to measure the size distribution of PRP-exos. The size distribution provides information about the size range and distribution of PRP-exos. The results showed reasonable size distribution data within the range of exosomes (Fig. 1A). TEM was used to examine the morphology of PRP-exos, and the result showed that they possess typical characteristics of exosomes, including the presence and shape of membrane vesicles (Fig. 1B). Additionally, western blotting was employed to identify PRP-exos by characteristic exosome surface markers, such as CD9, TSG101 and exosome-negative protein Calnexin (Fig. 1C). Extraction and characterization of PRP-exos. A Particle size distribution of PRP-exos measured by NTA. B Morphology of PRP-exos examined by TEM. Scale bar: 200 nm. C PRP-exos surface markers (CD9, TSG101) and exosome-negative protein Calnexin measured using Western Blotting. Combination of exosomes and cyclic peptide-modified β-TCP scaffold shows better therapeutic effects on cartilage defect After 8 weeks of treatment with PRP-exos, cyclic peptide-modified β-TCP scaffold and their combination, we subsequently assessed the repair level of damaged cartilage tissue using gross morphology examination and the ICRS criteria. General morphological observation revealed that the defect in the control group did not repair significantly at 8 weeks, mainly manifested as incomplete femoral condylar cartilage surface and exposed subchondral bone, while the other groups had different degrees of repair, but the new tissue was uneven. Among them, the group that combined PRP-exos with cyclic peptide-modified β-TCP scaffold has the best repair degree (Fig. 2A). In addition, the defect area was analyzed histologically using the ICRS classification of cartilage regeneration. The ICRS macroscopic scores revealed that PRP-exos groups, the cyclic peptide-modified β-TCP scaffold group and the combination group acquired significantly high scores when compared with the control group. Among those, the combination group showed much better repair of cartilage defect than that of the PRP-exos group alone and cyclic peptide-modified β-TCP scaffold group alone (Fig. 2B). The higher ICRS scores in combination group indicated better recovery of cartilage defect. Enhanced therapeutic effect of PRP-exos combined with cyclic peptide-modified β-TCP scaffold. A. Representative macroscopic images of the treatment groups. B Total ICRS scores for each sample group. *P < 0.05, **P < 0.01 compared with Control group. #P < 0.05, ##P < 0.01 compared with PRP-exos + β-TCP-cyclopeptide group. Pathological and microscopic evaluation of the therapeutic effect of PRP-exos combined with cyclic peptide-modified β-TCP scaffold HE stains were subsequently performed on the articular samples to assess subchondral bone regeneration. The results of the control group showed that the cartilage surface was irregular, the cartilage layer was thin. After treatment with PRP-exos or cyclic peptide-modified β-TCP scaffold alone, the damaged cartilage tissue was improved, and the combined use of PRP-exos and cyclic peptide-modified β-TCP significantly repaired the structure of the damaged cartilage tissue (Fig. 3A). The chondrocytes were counted several times under different sites through the microscope and multiple compared among the groups. The result revealed that the mean number of chondrocytes in the combination group was significantly higher than that in other groups (Fig. 4A). In addition, immunohistochemical results showed that PRP-exos group or cyclic peptide-modified β-TCP scaffold group alone significantly increased the expression levels of COL-2, Runx2 in damaged cartilage tissue according to the analysis of staining intensity. Combination group was more effective than PRP-exos or cyclic peptide-modified β-TCP scaffold group alone (Fig. 3B, C). Pathological and histological evaluation of the therapeutic effect of PRP-exos combined with cyclic peptide-modified β-TCP scaffold. A Hematoxylin and Eosin staining. B–C Immunohistochemical staining evaluation of COL-2 (B), RUNX2 (C) expression in the tissue (Scale bar: 5000 μm, 100 μm). The evaluation of the therapeutic effect of PRP-exos combined with cyclic peptide-modified β-TCP scaffold in chondrocytes counting, the levels of inflammatory factors and qRT-PCR target gene detection. A The chondrocytes counting in randomly selected high magnification fields. B Changes in serum MMP-3 levels in each group. C Serum TIMP-1 levels in each group. D–F Detection of inflammatory factors TNF-α (D), IL-1β (E), and IL-6 (F), in the tissue. G–I qRT-PCR analysis of COL-2 (G), RUNX2 (H) and SOX9 (I) expression changes. *P < 0.05, **P < 0.01 compared with Control group. #P < 0.05, ##P < 0.01 compared with PRP-exos + β-TCP-cyclopeptide group. Furthermore, COL-2, RUNX2 and SOX9 was detected by qRT-PCR to further assess the level of cartilage repair. The results demonstrated that the expression levels of COL-2, RUNX2 and SOX9 in the control group were low, while the expression levels of them in PRP-exos group and cyclic peptide-modified β-TCP scaffold groups were upregulated. The expression levels of them were highest in the group that combined PRP-exos with cyclic peptide-modified β-TCP scaffold (Fig. 4G–I). The above results confirmed that PRP-exos combined with cyclic peptide-modified β-TCP scaffold could significantly promote the cartilage defect repair and increase the neoformation of cartilage. Combined treatment downregulates MMP-3, upregulates TIMP-1 and reduces levels of inflammatory factors in osteoarticular cartilage MMP-3 is associated with cartilage degradation, and elevated levels of MMP-3 are correlated with the progression of osteoarticular cartilage. After treatment with PRP-exos or cyclic peptide-modified β-TCP scaffold alone, level of MMP-3 decreased significantly compared with the control group. Moreover, the combination group with PRP-exos and cyclic peptide-modified β-TCP scaffold had the lowest level of MMP-3 (Fig. 4B). TIMP-1 is a specific inhibitor of MMP-3, which was associated with cartilage repair and protection. The results showed that the control group had the lowest level of TIMP-1, which increased after treatment with PRP-exos or cyclic peptide-modified β-TCP scaffold alone. The group that combined PRP-exos with cyclic peptide-modified β-TCP scaffold had the highest level of TIMP-1 (Fig. 4C). TNF-α, IL-1β, and IL-6 are common inflammatory factors, and elevated levels of these factors are associated with exacerbated inflammatory responses, which can lead to osteoarthritis and even cartilage destruction. The control group had the highest levels of inflammatory factors. Both PRP-exos group and the cyclic peptide-modified β-TCP scaffold group alone were able to decrease the expression levels of TNF-α, IL-1β and IL-6. The group that combined PRP-exos with cyclic peptide-modified β-TCP scaffold had the best reduction effect. The above results confirmed that the combination group of PRP-exos and cyclic peptide-modified β-TCP scaffold could more effectively inhibit the expression of these inflammatory factors, thereby promoting cartilage repair (Fig. 4D–F). MiRNA sequencing analysis and PI3K/AKT signaling pathway may be involved in cartilage defect repair A total of six samples were included in this project, with the effective data volume (Clean Reads) ranging from 23.93 to 24.79 million. The genome alignment rate ranged from 17.11% to 51.49%, while the known miRNAs alignment rate ranged from 1.97% to 29.94%. The total number of known miRNAs aligned across all samples was 252. One differential comparison group was established, and a total of 91 differentially expressed miRNAs were detected. Figure 5A showed the box plot of differential miRNAs expression levels, and Table 2 provided detailed information on all differentially expressed miRNAs. The volcano plot (Fig. 5B) provided an overview of the overall distribution of differentially expressed miRNAs. Subsequently, unsupervised hierarchical clustering was performed on the differentially expressed miRNAs. MiRNAs clustered together might have similar biological functions, as shown in the heatmap (Fig. 5C). The results of KEGG enrichment analysis, ranked by -log10Pvalue for each entry, were presented in the bubble plot (Fig. 5D). The results indicated that the enriched functions of differentially expressed miRNAs mainly included Protein digestion and absorption, Glucagon signaling pathway, Oxytocin signaling pathway (Fig. 5D), etc. In this analysis, we focused on the PI3K/Akt signaling pathway. Activated PI3K/AKT signaling pathway has been found to promote chondrocyte proliferation and reduce apoptosis. Furthermore, microRNAs play an essential role in modulating PI3K/AKT signaling pathway and its effects on OA development. Therefore, the PI3K/AKT signaling pathway was believed to be closely related to the OA pathogenesis and cartilage destruction. In the protein–protein interaction network, it was also evident that the PI3K/AKT signaling pathway was significantly enriched (Fig. 5E). This enrichment suggested that the PI3K/AKT pathway played a central role in coordinating the interactions among proteins involved in chondrocyte proliferation, differentiation, and remodeling. Furthermore, the enrichment of the PI3K/AKT signaling pathway in the protein–protein interaction network indicated its extensive crosstalk with other signaling pathways, highlighting its integrative role in regulating various cellular processes related to chondrocyte proliferation and apoptosis. The significant enrichment of the PI3K/AKT signaling pathway underscored its importance in orchestrating the complex molecular mechanisms underlying alleviating osteoarthritis and repairing cartilage defect. miRNAs Sequencing analysis of PRP-exos. A Box plot of miRNA expression. B Volcanic map analysis. C Results of cluster analysis. D Enrichment analysis of differentially expressed miRNAs. The results of KEGG enrichment analysis indicate that PI3K/AKT pathway plays a key role in the coordination of osteocyte proliferation, differentiation, and remodeling. E In the protein-protein interaction network, the PI3K/AKT signaling pathway was enriched. Table 2Results of miRNA sequencing in exosomesmiRNAjdlog2FoldChangepValueqValueRegulationocu-miR-1-3p4,723,411,2612.609E−038.784E−03Upocu-miR-101-3p4,744,688,7362.180E−081.930E−07Upocj-miR-10b-3p− 4.667466746.130E−031.872E−02Downocu-miR-10b-5p− 1.7801366631.410E−057.510E−05Downocu-miR-12090-5p− 7.1998177075.050E−062.310E−05Down ocu-miR-122-5p1.4695181277.587E−042833E−03Upocu-miR-12Sb-2-3p− 7.5901139282.300E−071.660E−06Downocu-miR-125b-5p1.5586218026.254E−042.458E−03Upocu-miR-127-3p4.77180681 070E−268.540E−25Upocu-miR-12Ba-3p− 3.6946625777.227E−032.056E−02Downocu-miR-1296-5p− 6.982404159.039E−043.273E−03Downocu-miR-133a-3p− 6 0240382566730E−053215E−04Down ocu-miR-1343-3p− 6.5219968411 483E−046.444E−04Down ocu-miR-139-3p− 5.4284507822.040E−036.965E−03Down ocu-nniR-143-3p4.120039664.750E−222.270E−20Up ocu-miR-144-5p25.060177821.460E−101.840E−09Upocu-miR-145-3p− 3.4585144732.280E 051.185E−04Down ocu-miR-145-5p− 4.3093153295.869E−031.846E−02Downocu-miR-146b-5p6.2315237124.44SE−031.417E−02Upocu-miR-148a-Sp− 4.8756303936.166E−031.872E−02Downocu-miR-148b-3p3.4985714148439E−043103E−03Up ocu-miR-150-5p− 7.3131185625.810E−106.040E−09Down ocu-miR-151-3p1.5871839086.267E−031.872E−02Up ocu-miR-152-5p9.7209005SB7.991E−032.247E−02Up ocu-miR-15b-3p− 5.7392608726.375E−042.458E−03Downocu-miR-17-5p10.340458056.702E 031 953E−02Upocu-miR-181b-5p− 6.3716165357.780E−121.430E−10Down ocu-miR-183-5p− 5.2125880193.440E−051 677E−04Downocu-miR-185-3p− 6.0792464521.030E−044.644E−04Down ocu-miR-18a-3p− 5.2645711396.83SE−031.969E−02Downocu-miR-191-3p− 6.7864798124.990E 073.220E−06Downocu-miR-191-5p− 3.4876356391.703E−024.473E−02Downocu-miR-193a-5p− 6.9710735078.800E−162.630E−14Downocu-miR-193b-3p− 5.3870046267.476E−042.833E−03Down ocu-miR-195-3p− 6.2417293752.520E−051.281E−04Down ocu-miR-197-3p− 6.3865645492.557E−041 072E−03Downocu-miR-199a-3p4.4069944543.060E−061.740E−05Upocu-miR-204-3p4.819465244.020E−083.310E−07Up ocu-miR-205-5p− 4.540264 4 979 555E−032 595E−02Downocu-miR-20a-5p6.2982191723.243E 031.076E−02Upocu-miR-21-5p3.4850410542.590E−071 820E−06Up ocu-miR-215-5p− 9.3247023734.020E−115.650E−10Downocu-miR-219a-3p− 5.9751735291455E−046.439E−04Downocu-miR-22-5p− 5.7651677251.814E−047.741 E−04Down ocu-miR-223-3p− 6.6516909772.700E−051.346E−04Downocu-miR-223-5p− 7.5284876518.920E−054.101E−04Down ocu-miR-23b-5p− 5.3803346311413E−023.795E−02Downocu-miR 24–2-5p− 7.4825900611.700E−071.310E−06Downocu-miR-24-3p− 6.3253198856.190E−233.700E−21Downocu-miR-25-3p− 1.3676759836.696E−031.953E−02Downocu-miR-25-5p− 5.8523459416.331 E−042.458E−03Downocj-miR-27b-5p24.411105444.270E−104.860E 09Upocu-miR-28-3p− 7.7702813283.960E−149.460E−13Down ocu-miR-299-5p24.667577472.790E−103.330E−09Upocu-miR-29a-3p− 5.8493460741.370E−081.260E−07Downocu-miR-30a-3p− 7.586213522.230E−071.660E−06Downocu-miR-30E−3p− 5.589215541.060E−066.470E−06Down ocu-miR-326-3p− 5.116512593.977E−031.284E−02Down ocu-miR-328-3p− 7.8591005089.110E−087.250E−07Downocu-miR-342-3p− 7.2083266514040E−072.710E−06Downocu-miR-361-5p− 6.1907381981.6B0E−061.000E 05Downocu-miR-365-2-5p− 5.09752441.526E−035.285E−03Downocu-miR-365-3p− 5.8792339913.453E−041.423E−03Downocu-miR-369-3p10.179857549.276E−032.578E−Q2Up ocu-miR-375-3p− 7.9083114275.160E−491.230E−46Down ocu-miR-379-5p5.2732016361.850E−124.010E−11Upocu-miR-382-5p5.0747071839.420E−183.750E−16Up ocu-miR-409-3p6.515035981.550E−351.850E−33Up ocu-miR-409-5p25.898179033.420E−115.100E−10Upocu-miR-411-5p24.0322267.890E−107.860E−09Upocu-miR-423-3p− 3.3664939351.910E−113.140E−10Downocu-miR-423-5p− 1.3203699431.471E−035.169E−03Downocu-miR-425-3p− 6.4370720959.020E−064.900E−05Downocu-miR-432-5p5.4353954991.370E−174.690E−16Up ocu-miR-433-3p4.9451695052.190E−145.B10E−13Upocu-miR-485-5p7.6390983661.663E−024.415E−02Upocu-miR-486-5p− 3.7612001462.400E−082.050E−07Down ocu-miR-495-3p23.845961651.080E−091.03OE−08Up ocu-miR-501-3p− 8.6031033914.730E−105.140E−09Downocu-miR-502a-3p− 6.8647031061.900E−061.110E−05Down ocu-miR-532-3p− 5.1499652131.062E−033.787E−03Down ocu-miR-541-5p26.213156961.970E−113.140E−10Upocu-miR-574-3p− 7.0574769654.080E−072.710E−06Downocu-miR-590-3p− 4.0373126769.477E−032.595E 02Downocu-miR-6529-5p− 2.3008147041.010E−101.340E−09Downocu-miR-671-3p− 5.8027729943.367E−031.102E−02Down ocu-miR-672-5p− 5.9783391487.490E−053.5O8E−04Downocu-miR-7180-3p− 4.6057766076.263E−031.872E−02Down ocu-miR-744-5p− 7.0256156348.480E−075.330E−06Down ocu-miR-885-5p− 5.4682662284.853E−041.966E−03Down ocu-miR-99a-5p− 3.5495313823.140E−126.260E−11Down Results of miRNA sequencing in exosomes Discussion Once damaged, articular cartilage has limited ability to regenerate itself, and poor management of lesions can lead to disability [36]. Intra-articular injection PRP is a promising method to solve this problem [37]. Many basic scientific and clinical studies have shown that PRP contains a variety of growth factors, which can affect inflammation, angiogenesis, cartilage protection and cellular proliferation and differentiation after articular cartilage injury through different pathways [38]. Previous studies have reported that the primary mechanism of PRP on osteoarthritis probably involves the exosomes derived from PRP [39]. Through the isolation of exosomes from PRP, Torreggiani et al. first reported the effects of PRP-exos on histological regeneration [40]. Besides, some studies have reported that PRP-exos have an underlying beneficial effect in the treatment of cartilage injury through the promotion of osteogenic differentiation of BMSCs [41]. In this study, we successfully isolated exosomes from platelet-rich plasma (PRP), which were confirmed the characterization with typical exosome morphology [42], and had exosome surface markers, such as CD9, TSG101, as well as exosome-negative protein Calnexin [43, 44]. These findings were consistent with previous studies demonstrating the successful isolation and identification of exosomes from PRP [39]. Chondrocytes-loaded β-tricalcium phosphate (β-TCP) scaffold has been explored in the repair of osteochondral defect and showed good regeneration behaviors [45]. However, β-TCP lacks biological stimulatory activity, adhesion, expansion, and proliferation of chondrocytes [46]. Moreover, its absorption is faster than the new bone formation [47]. These make β-TCP not an ideal biomaterial to be applied in the treatment of cartilage defect. Surface modification is a commonly used and effective method. It has been reported that the surface of demineralized bone matrix particles was modified by bone marrow-derived mesenchymal stem cell (BMSC) affinity peptide to promote cartilage regeneration [48]. The cyclic peptide (DWRVIIPPRPSA) was designated as chondrocyte-affinity peptide (CAP), which was used to modify the surface of the β-TCP scaffold to promote the adhesion and proliferation of chondrocytes, thus promoting the repair of cartilage defect [49]. In this study, we investigated the therapeutic effects and underlying mechanisms of PRP-exos combined with cyclic peptide-modified β-TCP scaffold in the treatment of rabbit knee cartilage defect. Our results demonstrated that this combination therapy effectively promoted cartilage repair and functional improvement. The evaluation of cartilage healing rate and ICRS score revealed that the combination of PRP-exos and cyclic peptide-modified β-TCP scaffold had superior therapeutic effects. This suggests that the combination therapy enhances the regenerative potential of the scaffold and promotes cartilage repair. The improved tissue repair degree observed in the histological analysis further supports the efficacy of the combination therapy in promoting cartilage regeneration. The expression analysis of COL-2, RUNX2, and SOX9, which are important markers of chondrogenesis and cartilage function, demonstrated that the combination therapy upregulated their expression levels [50]. The upregulation of COL-2, RUNX2 and SOX9 expression suggests enhanced chondrogenic differentiation and maturation of chondrocytes, which are essential for cartilage repair and regeneration [51]. The levels of inflammatory factors, including TNF-α, IL-1β, and IL-6, were significantly reduced in the combination therapy group. These findings are consistent with previous studies showing the pro-proliferative and pro-migratory effects of PRP-exos on various cell types [52]. MMPs have extensive in proteolytic capacity and are involved in remodeling the extracellular matrix of connective tissue, and inhibition of MMPs has been shown to reduce the severity of cartilage degradation in osteoarthritis [53]. Lu et al. [54] founded that PRP could improve articular cartilage damage by inhibiting the toll-like receptor-2(TLR2)-mediated signaling pathway, inhibiting the expression of MMP-1, MMP-3, and MMP-13, reducing the degradation of extracellular matrix in articular cartilage. Tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) is a specific inhibitor of MMP-3, which protects cartilage tissue [55]. Zhao et al. [56] founded that indicating that both PRP-exos and PRP can increase the serum TIMP-1 concentration, thereby inhibiting MMP-3 degradation of cartilage tissue. In this experiment, the group that combined PRP-exos with cyclic peptide-modified β-TCP scaffold had the lowest level of MMP-3 and the highest level of TIMP-1, which indicated the cartilage repair ability of combination group, and the result was consistent with previous research. The inhibition of chondrocyte apoptosis by PRP-exos further supports their anti-apoptotic properties, which are crucial for maintaining chondrocyte viability and preventing cartilage tissue degeneration. MiRNA are small noncoding RNA of 1 to 25 nucleotides that repress the translation of and/or cleave mRNA by partially base pairing with the untranslated regions and/or coding regions of their target transcripts [57]. Studies has proved that several miRNAs, such as miR-140, are implicated in the pathogenesis of OA and cartilage repair [58]. Exosomes contain proteins, mRNA, and miRNA, and protect miRNA from RNase [59], and miRNA can transmit information between cells and between tissues [59]. Therefore, in this study, miRNA sequencing analysis of PRP-exos was performed and compared with activated PRP. A total of 91 differentially expressed miRNAs were detected. KEGG enrichment analysis demonstrated that cartilage repair effect of PRP-exos may be related to the PI3K/AKT signaling pathway, which was further confirmed by protein–protein interaction network. PI3K/AKT signaling pathway is an important and very complex signaling pathway, and more than 150 proteins have been identified to participate in this pathway [60]. It has been reported that PI3K/AKT signaling pathway plays an important role in many cellular processes, including cell cycle, cell survival, inflammation, metabolism, and apoptosis [61]. Moreover, increased evidence supports the involvement of PI3K/AKT signaling pathway in OA development [62]. Sun et al. believes that the PI3K/AKT signaling pathway mainly intervenes in OA through the following three aspects, including cartilage degeneration, synovial inflammation, and subchondral bone sclerosis [63]. In particular, numerous studies suggest that the PI3K/AKT signaling pathway are required for cartilage homeostasis [64], inflammatory response [65], chondrocyte proliferation and apoptosis [66], autophagy [67]. As expected, miRNAs play an essential role in modulating PI3K/AKT signaling pathway and its effects on OA development. Jiang et al. found that miR-149 is involved in the pathogenesis of OA by regulating the PI3K/AKT axis [68]. Overall, the role and function prediction of the PI3K/AKT signaling pathway regulated by miRNAs in PRP-exos in this study are basically consistent with the results of previous studies, and the PI3K/AKT signaling pathway is critical in the pathogenesis of OA. However, there remain many prominent issues to be addressed. Therefore, further research is needed to elucidate the exact mechanisms of the PI3K/AKT signaling pathway in the combined treatment of PRP-exos and cyclic peptide-modified β-TCP scaffold to provide a more comprehensive theoretical basis for clinical applications. Conclusion In the present study, we successfully isolated, purified and identified exosomes from PRP. Furthermore, PRP-exos combined with cyclic peptide-modified β-TCP scaffold could effectively promote cartilage defect repair, because of up-regulation of TIMP-1 expression and down-regulation of MMP-3 expression as well as inflammatory factor expression mediated by the combination. The results of miRNAs sequencing analysis revealed that the therapeutic effect may be related to the PI3K/AKT signaling pathway. Further studies are warranted to validate these findings and explore the clinical applications of PRP-exos in the field of cartilage tissue engineering and regenerative medicine. In conclusion, PRP-exos combined with cyclic peptide-modified β-TCP scaffold can effectively promote cartilage repair and functional improvement in rabbit knee cartilage defect. These findings highlight the potential of PRP-exos as a promising therapeutic strategy for the treatment of cartilage defect and provide insights into the underlying mechanisms involved in their regenerative effects. Acknowledgements Not applicable. Abbreviations Platelet-rich plasma Exosomes derived from PRP Tricalcium beta-phosphate International Cartilage Repair Society Bone mesenchymal stem cells Enzyme-linked immunosorbent assay Interleukin 1 beta Nanoparticle tracking analysis Transmission electron microscope Osteoarthritis Osteoarthritis Research Society International Runt-related transcription factor 2 Transforming growth factor-β Tumor necrosis factor-α Authors’ contributions X.L.: performed the entire study, analyzed the results, and wrote the manuscript. R.C., G.C.: performed the animal experiments, analyzed the results. R.F.: supervised the entire study, provided critical revision. K.L.: conceptualized the idea, supervised the entire study, analyzed the results, and provided critical revision. All authors have read and provided their consent to the final version of the manuscript. Funding This study received funding from Clinical medicine technology innovation program of Jinan (NO. 202225048), Traditional Chinese medicine technology project of Shandong Province (No. Q-2023038), Medical and health technology development program of Shandong Province (No. 2019WS467) and Transverse technology project (swscg01-2023-164). Availability of data and materials Data of the present study are publicly available and may also be available from the corresponding authors upon request. Declarations Ethics approval and consent to participate The present study was performed in compliance with Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocol was approved by the Experimental Animal Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University (No. 2023-0026). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Rongjie Feng, Email: frongjie@163.com. Kechun Liu, Email: qllkch2024@126.com. References Associated Data Data Availability Statement Data of the present study are publicly available and may also be available from the corresponding authors upon request.